RT Journal Article
SR Electronic
T1 The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154922
DO 10.1101/2020.07.15.20154922
A1 Michael W. Dzierlenga
A1 Debra R. Keast
A1 Matthew P. Longnecker
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.07.15.20154922.abstract
AB Fiber-rich food intake has been associated with lower serum concentrations of perfluoroalkyl substances (PFAS) in some studies and dietary fiber was related to lower serum PFAS in a recent study. Given the previous epidemiologic data suggesting that fiber might decrease serum PFAS concentrations, we examined the relation of serum PFAS concentrations to intake of dietary fiber in National Health and Nutrition Examination Survey (NHANES) data. We examined the PFAS-fiber association among 6,482 adults who participated in the NHANES, 2005-2016. Fiber intake was estimated based on two 24-hour diet recalls. We adjusted the models for determinants of PFAS and potentially confounding factors such as intake of foods reported to increase PFAS exposure. Results were expressed as the percent difference in PFAS concentration per interquartile range (IQR) increase in fiber (and 95 percent confidence interval), and the NHANES sampling parameters were used to make the results generalizable to the U.S. The adjusted percent difference in perfluorooctanoic acid (PFOA) per IQR increase in fiber was −3.64 (−6.15, −1.07); for perfluorooctane sulfonic acid (PFOS) was −6.69 (−9.57, −3.73), and for perfluorononanoic acid (PFNA) was −8.36 (−11.33, −5.29). These results suggest that dietary fiber increases the gastrointestinal excretion of PFOA, PFOS, and PFNA. Because fiber also lowers serum cholesterol, in some studies of the serum cholesterol-PFAS relationship confounding by fiber may be worth evaluating.Competing Interest Statement3M, the company that funded this research, previously used PFOA and precursors to PFOS in manufacturing. 3M was not involved in the preparation of the manuscript. The authors retained sole control of the manuscript content and the findings, and statements in this paper are those of the authors and not those of the authors employer or the sponsors. No authors were directly compensated by 3M. This project was funded through a contract between 3M and Ramboll, an international science and engineering company that provided salary compensation to the authors. None of the authors are currently engaged to testify as experts on behalf of the sponsors in litigation related to the compound discussed in this manuscript.Funding Statement3M, the company that funded this research, previously used PFOA and precursors to PFOS in manufacturing. 3M was not involved in the preparation of the manuscript. The authors retained sole control of the manuscript content and the findings, and statements in this paper are those of the authors and not those of the authors employer or the sponsors. No authors were directly compensated by 3M. This project was funded through a contract between 3M and Ramboll, an international science and engineering company that provided salary compensation to the authors. None of the authors are currently engaged to testify as experts on behalf of the sponsors in litigation related to the compound discussed in this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was not required as this work was conducted using publicly available data (the NHANES survey).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.